Research Papers:

20(S)-Ginsenoside Rg3 is a novel inhibitor of autophagy and sensitizes hepatocellular carcinoma to doxorubicin

Dong-Gun Kim, Kyung Hee Jung, Da-Gyum Lee, Jung-Ho Yoon, Kyeong Sook Choi, Sung Won Kwon, Han-Ming Shen, Michael J. Morgan, Soon-Sun Hong and You-Sun Kim _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2014; 5:4438-4451. https://doi.org/10.18632/oncotarget.2034

Metrics: PDF 3349 views  |   HTML 4420 views  |   ?  


Dong-Gun Kim1, Kyung Hee Jung2, Da-Gyum Lee1, Jung-Ho Yoon1, Kyeong Sook Choi1, Sung Won Kwon3, Han-Ming Shen4, Michael J. Morgan5, Soon-Sun Hong2, You-Sun Kim1

1 Department of Biochemistry and Department of Biomedical Sciences, Ajou University School of Medicine, Suwon

2 College of Medicine, Inha University, Incheon

3 College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea

4 Saw Swee Hock School of Public Health, National University of Singapore, Singapore

5 Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado


You-Sun Kim, email:

Soon-Sun Hong, email:

Keywords: Rg3, autophagy, HCC, doxorubicin, cell death

Received: March 25, 2014 Accepted: May 27, 2014 Published: May 28, 2014


Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. High mortality from HCC is mainly due to widespread prevalence and the lack of effective treatment, since systemic chemotherapy is ineffective, while the targeted agent Sorafenib extends median survival only briefly. The steroidal saponin 20(S)-ginsenoside Rg3 from Panax ginseng C.A. Meyer is proposed to chemosensitize to various therapeutic drugs through an unknown mechanism. Since autophagy often serves as cell survival mechanism in cancer cells exposed to chemotherapeutic agents, we examined the ability of Rg3 to inhibit autophagy and chemosensitize HCC cell lines to doxorubicin in vitro. We show that Rg3 inhibits late stage autophagy, possibly through changes in gene expression. Doxorubicin-induced autophagy plays a protective role in HCC cells, and therefore Rg3 treatment synergizes with doxorubicin to kill HCC cell lines, but the combination is relatively nontoxic in normal liver cells. In addition, Rg3 was well-tolerated in mice and synergized with doxorubicin to inhibit tumor growth in HCC xenografts in vivo. Since novel in vivo inhibitors of autophagy are desirable for clinical use, we propose that Rg3 is such a compound, and that combination therapy with classical chemotherapeutic drugs may represent an effective therapeutic strategy for HCC treatment.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2034